Can US FDA Save Pharma From Price Controls?
FDA Commissioner Scott Gottlieb is making drug pricing a big theme of his first weeks as FDA commissioner. Will it be enough to head off other executive or legislative action on the issue?
You may also be interested in...
US FDA commissioner says he would be happy to work with Congress on a legislative solution on the issue, but emphasized his priority is for the agency to develop a system itself to discourage REMS abuse.
There's lots of buzz about drug pricing actions, be they executive or legislative. But the die is cast for this year: real reforms will have to wait.
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.